| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 66.1 Billion |
| Market Size in 2025 | USD 73.6 Billion |
| Market Size by 2032 | USD 165.4 Billion |
| Projected CAGR | 12.3% |
| Largest Region | North America |
| Fastest Growing Region | APAC |
| Market Structure | Consolidated |
Explore the market potential with our data-driven report
The global biomarkers market size was USD 66.1 billion in 2024, which is predicted to reach USD 165.4 billion by 2032, growing at a CAGR of 12.3% during 2025–2032.
This can be ascribed to the rising prevalence of chronic diseases and advancements in the technologies used for the development of biomarkers and biomarker-based diagnostic tests, such as biomarker signatures, which are making neurological diseases more treatable. Additionally, the increase in the number of infectious and rare genetic disease cases, as well as the rise in the geriatric population, will propel the utilization of such agents in the coming years. These agents are used in diagnostics for checking the presence of or risk of a specific disease; safety assessments, and drug discovery and development.
Biomarkers are important in personalized medicine because they can be utilized for a variety of functions, such as diagnosis, prognosis, and the creation of targeted therapies for numerous diseases. Therefore, personalized medicine has gained popularity as a result of several limitations in the diagnosis and treatment of conventional diseases. Patients with cancer and immunological disorders are increasingly being offered personalized treatment approaches based on their unique clinical and genetic characteristics. The rising demand for personalized medicine is one of the main factors driving the demand for biological markers.
Companion diagnostics and biological markers are vital in the practice of medicine as they improve disease diagnosis, treatment, and monitoring. These approaches allow doctors to determine which patients will respond to a specific medication or treatment desirably. These diagnostic tests are frequently performed in conjunction with a particular medication. For instance, in August 2025, the FDA approved the Oncomine Dx Target test created by Thermo Fisher Scientific Inc. for the biomarker-driven testing of non-small-cell lung cancer.
Thus, the demand for new biomarker-based tests is driven by the growing use of companion diagnostics as a tool for personalized treatments. Furthermore, the rising investment by the key market players to develop companion diagnostics approaches is a key driving factor for the market.
The diagnostics category commanded the largest market share in 2024, accounting for 40% of the global biomarkers market. The category is driven by the widespread integration of biomarker testing in routine clinical practice and the expanding menu of FDA-approved diagnostic biomarkers. Healthcare providers increasingly rely on biomarker-based diagnostics for disease screening, diagnosis confirmation, and treatment monitoring across multiple therapeutic areas. The implementation of liquid biopsy tests for cancer detection and monitoring has particularly accelerated diagnostic biomarker adoption, with tests capable of detecting minimal residual disease and predicting treatment resistance gaining rapid clinical acceptance.
Drug discovery & development represent the fastest-growing application category, projected to expand at a CAGR during 2025–2032. Pharmaceutical companies are leveraging biomarkers throughout the drug development continuum, from target identification and lead optimization to clinical trial design and post-market surveillance. The Biotechnology Innovation Organization reports that drugs developed with biomarker strategies have a 25.9% likelihood of approval from Phase I, compared to 8.4% for those without biomarker integration. This substantial improvement in success rates has prompted pharmaceutical companies to embed biomarker strategies early in drug development programs, particularly for oncology and rare disease therapeutics, wherein patient stratification is critical for demonstrating clinical benefit.
These applications are covered:
The consumables category dominated the market in 2024 with a 55% share, reflecting the recurring nature of biomarker testing and the continuous need for reagents, assay kits, and other consumable products in clinical and research laboratories. The high volume of routine biomarker tests performed globally, combined with the introduction of novel biomarker assays requiring specialized reagents, sustains strong demand for consumables. Additionally, the shift toward multiplex biomarker panels that simultaneously measure multiple analytes has increased reagent consumption per test, further driving category growth.
Services are the fastest-growing product category during the forecast period. The complexity of biomarker discovery, validation, and clinical implementation has created substantial demand for specialized service providers offering expertise in biomarker development, clinical trial support, and companion diagnostic development. Contract research organizations increasingly offer comprehensive biomarker services spanning from early discovery through regulatory approval, addressing the technical and regulatory challenges that many organizations face in developing biomarker-based solutions. The growing outsourcing trend in pharmaceutical and biotechnology companies, driven by the need to access specialized expertise and advanced technologies while managing costs, continues to fuel service category expansion.
These product types are covered:
The efficacy biomarkers category held the largest market share, of 60%, in 2024, driven by their critical role in demonstrating therapeutic benefit and supporting drug approval decisions. Regulatory agencies increasingly require efficacy biomarker data to substantiate clinical trial endpoints, particularly for accelerated approval pathways where surrogate endpoints serve as primary efficacy measures. The oncology field has particularly embraced efficacy biomarkers, with tumor response markers, progression-free survival indicators, and minimal residual disease markers becoming standard components of cancer drug development programs.
Safety biomarkers represent the fastest-growing category, with a projected CAGR of approx. 12.5% during forecast period. The pharmaceutical industry's heightening focus on drug safety, combined with regulatory mandates for comprehensive safety monitoring, has elevated the importance of safety biomarkers in drug development and post-market surveillance. The FDA's Biomarker Qualification Program has qualified multiple safety biomarkers for kidney, liver, and cardiac toxicity assessment, providing standardized tools for safety evaluation across drug development programs. The implementation of these qualified biomarkers has enhanced the ability to detect organ-specific toxicities earlier in development, potentially saving billions in late-stage failure costs.
These types are covered:
The cancer category dominated the market with a 35% share in 2024, reflecting the extensive use of biomarkers across the oncology care continuum from screening and diagnosis through treatment selection and monitoring. The proliferation of targeted therapies and immunotherapies in oncology has made biomarker testing essential for optimal treatment selection, with companion diagnostics required for over 40 FDA-approved cancer drugs. According to the National Cancer Institute, comprehensive genomic profiling has become standard practice for advanced cancers, with tests analyzing hundreds of genes to identify actionable mutations and guide precision therapy selection.
Neurological disorders represent the fastest-growing category, with a projected CAGR during 2025–2032, driven by breakthrough discoveries in neurodegenerative disease biomarkers and the urgent need for early detection tools. The Alzheimer's Association reports that blood-based biomarkers for Alzheimer's disease, including phosphorylated tau and amyloid-beta ratios, have achieved diagnostic accuracy exceeding 90%, potentially revolutionizing dementia diagnosis and enabling earlier therapeutic intervention. The development of these accessible biomarkers addresses a critical gap in neurological disease management, where traditional diagnostic approaches often identify disease only after significant neurological damage has occurred.
Globally, around 12.2 million new strokes occur each year, and it is the second-leading cause of death and a major cause of long-term disability, with higher incidence in low- and middle-income countries. An estimated 10 million new cases of dementia are diagnosed annually. Alzheimer's disease accounts for 60–70% of these cases, with the total number expected to rise sharply due to global population aging.
These disease areas are covered:
Drive strategic growth with comprehensive market analysis
North America held the largest market share, of approximately 40%, in 2024, attributed to the region's advanced healthcare infrastructure, substantial research funding, and rapid adoption of precision medicine approaches. The presence of leading pharmaceutical and biotechnology companies, coupled with favorable reimbursement policies for biomarker testing, has created a robust ecosystem for biomarker development and commercialization. The National Cancer Institute alone invested over USD 7.3 billion in cancer research in 2023, with significant portions allocated to biomarker discovery and validation programs.
The U.S. dominates the North American market, accounting for 85% of the regional revenue, driven by the country's leadership in biomarker research and clinical implementation. According to the Centers for Medicare & Medicaid Services, Medicare coverage for biomarker testing has expanded significantly, with over 170 biomarker tests now covered under various national coverage determinations. The implementation of the Precision Medicine Initiative and the Cancer Moonshot program has further accelerated biomarker adoption, with federal investments exceeding USD 2 billion annually in precision medicine research. The integration of biomarker testing into clinical guidelines by organizations, including the National Comprehensive Cancer Network has standardized biomarker use across oncology practices, ensuring consistent implementation of precision medicine approaches.
Over 48% of the adults in the U.S. have some form of cardiovascular disease, according to the American Heart Association. In the U.S., six in ten adults have a chronic disease, and four in ten adults have two or more chronic conditions, according to the Centers for Disease Control and Prevention.
Asia-Pacific is projected to be the fastest-growing regional market, with a CAGR of 13.0% during 2025–2032, driven by rapidly expanding healthcare expenditure, increasing chronic disease prevalence, and growing government investments in precision medicine infrastructure. The region's large patient population, combined with improving diagnostic capabilities and rising healthcare awareness, creates substantial opportunities for biomarker market expansion. According to the Asian Development Bank, healthcare spending in Asia is expected to reach USD 4.3 trillion by 2030, with significant investments directed toward advanced diagnostic technologies, including biomarker testing.
China leads the Asia Pacific growth trajectory, with the government's Healthy China 2030 initiative allocating RMB 1.6 trillion for healthcare modernization, including precision medicine programs. The Chinese National Health Commission has established over 100 precision medicine centers nationwide, creating infrastructure for large-scale biomarker research and clinical implementation.
India's biomarkers market is experiencing rapid expansion, driven by the country's growing biotechnology sector and increasing prevalence of non-communicable diseases. The Indian Council of Medical Research reports that 65% of deaths in India result from non-communicable diseases, creating urgent demand for biomarker-based diagnostic and monitoring solutions.
The regions and countries analyzed in this report are:
The global biomarkers market is characterized by a consolidated structure, with the top 10 players collectively controlling a significant portion of the market share. This consolidation can be attributed to high barriers to entry, such as substantial investments in research and development, complex regulatory requirements, and the need for extensive clinical evidence to validate biomarkers. Leading companies maintain their market position through continuous innovation in biomarker discovery platforms, strategic partnerships with pharmaceutical companies for companion diagnostic development, and the expansion of their biomarker testing menus.
Research and development investments are a critical component for these companies, enabling them to advance biomarker technologies and stay ahead in the competitive landscape. The competitive dynamics in the biomarkers market are intensifying, with companies increasingly pursuing strategic acquisitions to enhance their biomarker capabilities and expand their therapeutic areas.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages